-+ 0.00%
-+ 0.00%
-+ 0.00%

Editas wins Australian clearance to start Phase 1/2 EDIT-401 trial in HeFH patients

PUBT·10/08/2026 11:02:21
Listen to the news
Editas wins Australian clearance to start Phase 1/2 EDIT-401 trial in HeFH patients
  • Editas Medicine received Australian ethics clearance to start dosing in a Phase 1/2 trial of EDIT-401 for HeFH.
  • The program completed the TGA Clinical Trial Notification process; a New Zealand regulatory review is ongoing.
  • First safety and tolerability data are expected in Q1 2027; Part 1 topline safety and efficacy are targeted for later 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080700PRIMZONEFULLFEED9841763) on October 08, 2026, and is solely responsible for the information contained therein.